Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 6/20 | 0.63 |
| ▸ | DRD3 | P35462 | 3/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8648859 | 0.93 | DRD2 (0.68) | ADRA1AADRA1DADRA1BDRD2DRD3 | |
| SCHEMBL9035759 | 0.81 | ADRA1A (0.80) | ADRA1AADRA1DADRA1BDRD2DRD3 | |
| SCHEMBL16026529 | 0.80 | THRB (0.61) | ADRA1AADRA1DADRA1B | |
| SCHEMBL29922137 | 0.80 | THRB (0.61) | ADRA1AADRA1DADRA1B | |
| SCHEMBL6070007 | 0.80 | MAPT (0.51) | ADRA1AADRA1DADRA1BDRD2DRD3 | |
| SCHEMBL6069904 | 0.80 | MAPT (0.51) | ADRA1AADRA1DADRA1BDRD2DRD3 | |
| SCHEMBL5442134 | 0.80 | ADRA1D (1.00) | ADRA1AADRA1DADRA1BDRD2DRD3 | |
| SCHEMBL74384 | 0.79 | ADRA1A (0.85) | ADRA1AADRA1DADRA1BDRD2DRD3 | |
| SCHEMBL6475458 | 0.79 | HTR1A (0.66) | ADRA1AADRA1DADRA1BHTR1A | |
| SCHEMBL6475314 | 0.79 | HTR1A (0.62) | ADRA1AADRA1DADRA1BDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1123926-A1 | Piperazine derivatives for treatment of CNS disorders | JOHN WYETH & BROTHER LIMITED (GB) | 2001-08-16 | — | — | EP | disclosed |
| EP-0690845-B1 | PIPERAZINE DERIVATIVES AS 5-HT1A LIGANDS | WYETH JOHN & BROTHER LTD (GB) | 1998-09-09 | — | — | EP | disclosed |
| US-5693642-A | ANXIOLYTIC AND HYPOTENSIVE AGENTS; ANTIDEPRESSANTS; PSYCHOLOGICAL DISORDERS; CONTROLLERS OF SLEEP/WAKE CYCLE, EATING AND SEXUAL DISORDERS | JOHN WYETH & BROTHER LTD. (GB) | 1997-12-02 | — | — | US | disclosed |
| EP-0690845-A1 | PIPERAZINE DERIVATIVES AS 5-HT1A LIGANDS | JOHN WYETH & BROTHER LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| EP-0502169-B1 | PIPERAZINE DERIVATIVES | WYETH JOHN & BROTHER LTD (GB) | 1996-01-03 | — | — | EP | disclosed |
| US-5369103-A | Anxiolytic agents, cental nervous system disorders | JOHN WYETH & BROTHER, LIMITED (GB) | 1994-11-29 | — | — | US | disclosed |
| WO-1994021610-A1 | PIPERAZINE DERIVATIVES AS 5-HT1A LIGANDS | JOHN WYETH & BROTHER LIMITED (GB) | 1994-09-29 | — | — | WO | disclosed |
| US-5346896-A | 1-(aryl or heteroaryl)-4[ω-(aryl or heteroaryl)ω-(aryl or heteroaryl)alkylene]piperazines | JOHN WYETH & BROTHER, LIMITED (GB) | 1994-09-13 | — | — | US | disclosed |
| EP-0506905-A1 | PIPERAZINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1992-10-07 | — | — | EP | disclosed |
| EP-0502169-A1 | PIPERAZINE DERIVATIVES. | WYETH JOHN & BROTHER LTD (GB) | 1992-09-09 | — | — | EP | disclosed |
| WO-1992006960-A1 | PIPERAZINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1992-04-30 | — | — | WO | disclosed |
| WO-1992006082-A1 | PIPERAZINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1992-04-16 | — | — | WO | disclosed |